Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Arformoterol Tartrate Inhalation Solution, 15 mcg (base)/2 ml Unit-dose Vial. In this regard, the company has enclosed a press release.
The above information is a part of company’s filings submitted to BSE.